- Home
- BNL vs MRUS Comparison
BNL vs MRUS Comparison
Compare BNL & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNL
- MRUS
- Stock Information
- Founded
- BNL 2007
- MRUS 2003
- Country
- BNL United States
- MRUS Netherlands
- Employees
- BNL N/A
- MRUS N/A
- Industry
- BNL Real Estate Investment Trusts
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BNL Real Estate
- MRUS Health Care
- Exchange
- BNL Nasdaq
- MRUS Nasdaq
- Market Cap
- BNL 3.4B
- MRUS 3.6B
- IPO Year
- BNL 2020
- MRUS 2016
- Fundamental
- Price
- BNL $18.61
- MRUS $51.74
- Analyst Decision
- BNL Hold
- MRUS Strong Buy
- Analyst Count
- BNL 6
- MRUS 10
- Target Price
- BNL $18.25
- MRUS $84.00
- AVG Volume (30 Days)
- BNL 994.1K
- MRUS 602.5K
- Earning Date
- BNL 10-30-2024
- MRUS 10-31-2024
- Dividend Yield
- BNL 6.20%
- MRUS N/A
- EPS Growth
- BNL N/A
- MRUS N/A
- EPS
- BNL 0.83
- MRUS N/A
- Revenue
- BNL $425,817,000.00
- MRUS $35,193,000.00
- Revenue This Year
- BNL N/A
- MRUS N/A
- Revenue Next Year
- BNL $4.16
- MRUS $70.55
- P/E Ratio
- BNL $22.34
- MRUS N/A
- Revenue Growth
- BNL N/A
- MRUS N/A
- 52 Week Low
- BNL $13.68
- MRUS $19.81
- 52 Week High
- BNL $19.15
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- BNL 56.42
- MRUS 52.95
- Support Level
- BNL $18.05
- MRUS $50.80
- Resistance Level
- BNL $18.81
- MRUS $52.89
- Average True Range (ATR)
- BNL 0.27
- MRUS 1.59
- MACD
- BNL -0.00
- MRUS 0.20
- Stochastic Oscillator
- BNL 54.96
- MRUS 66.45
About BNL Broadstone Net Lease Inc.
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.